Figure 1From: Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032Chest wall lesions before treatment with PLX4032 (A) and on the first day of the fifth treatment cycle (B).Back to article page